Mitochondrial biology beyond the energy metaphor

Mitochondria integrate membrane organization, energy transfer, genetics, and quality control. A claim to improve mitochondrial function becomes meaningful only when the specific process and measurement are identified.

Mitochondrial compartments

The mitochondrion has an outer and inner membrane, with a space between them and a matrix delimited by the inner membrane. The cristae extend and organize this membrane. This arrangement is important because reactions do not occur in an undifferentiated compartment. The respiratory complexes and ATP synthase are associated with the inner membrane. Numerous metabolic reactions occur in the matrix. This distinction will be useful when reading that a compound is targeted to a membrane or accumulates in a compartment. Localization is an experimental question that requires its own demonstration.

Electron transfer and gradients

During mitochondrial respiration, electron transfer is coupled to proton movements across the inner membrane. The result is an electrochemical gradient that stores usable energy. Oxygen participates as the final electron acceptor in the respiratory chain. These relationships explain why membrane integrity and complex activity are important. They also show that oxygen consumption and energy production are not identical measures. The coupling between processes modifies their relationship. When interpreting an assay, we must identify whether respiration, membrane potential, or energy production was measured. These results do not represent equivalent mitochondrial enhancements. Interpret each measurement within the process it actually describes, rather than treating the measurements as interchangeable.

ATP synthesis and demand

ATP synthase uses the energy associated with the proton gradient to form ATP. This molecule participates in numerous reactions that require energy transfer. Its availability depends on production and consumption within a cell with variable demands. It should not be interpreted as a static reserve that always increases with any beneficial intervention. Nor does a single concentration measurement describe the entire respiratory capacity. An experiment can study production flux, content, or response to demand. These are different questions. When evaluating a peptide, we need to maintain the specific measurement and the context. A single biochemical result does not, by itself, demonstrate greater strength or endurance.

Two genomes

Mitochondria contain their own genetic material, but most of their proteins originate from nuclear genes. Many are synthesized outside the mitochondria and require transport systems to reach their destination. Therefore, we cannot describe all mitochondrial function as independent of the nucleus. We must also distinguish between a sequence encoded in the mitochondrial genome and a molecule designed to target that organelle. Both may appear in discussions about peptides, but their origins are not equivalent. This distinction will be important when comparing MOTS-c, humanin, and elamipretide. Before attributing common properties, we must identify which molecule was studied and what exactly the proposed relationship with the mitochondria means.

Read the 2001 humanin cell-study paper together with its published correction: the original study did not establish the sequence’s nuclear origin or natural peptide production in vivo. The correction is not a retraction; it limits what the original experiment established and does not settle later humanin research or establish clinical benefit. Published correction, PMC60143

Cardiolipin

Cardiolipin is a lipid characteristic of the inner mitochondrial membrane. Its relationship with the organization and function of this membrane is relevant to certain diseases and therapeutic strategies. It is not a peptide, although some peptides are studied for their interaction with it. Barth syndrome offers a clinical example related to alterations in its metabolism. It is important to maintain the identity of the component and its location. Stating that a compound interacts with a membrane does not demonstrate that it corrects any mitochondrial disease. Clinical utility depends on the specific alteration, the intervention, and the results demonstrated in patients.

Quality control and mitophagy

Mitochondrial function also depends on mechanisms that maintain or eliminate damaged components. Narendra and colleagues studied the recruitment of Parkin to damaged mitochondria and its relationship to clearance by autophagy. This cell-based work helped characterize a quality control pathway. However, it does not establish that increasing any autophagy marker automatically improves human health. The ability to complete the process, the cell type, and the experimental situation also matter. A change in proteins can represent different phases of a response. Therefore, we must distinguish between a mechanism observed in cells and a demonstrated benefit in patients. This distinction prevents us from turning the word "mitophagy" into a therapeutic promise without a defined clinical outcome.

Measuring a defined function

Mitochondrial studies employ measures that describe distinct levels of organization. Cellular respiration reports on oxygen consumption under specific conditions. The production of ATP assesses another aspect of metabolism. A gait or strength test describes a person's performance, influenced by multiple systems. There is no automatic equivalence between these results. A favorable change in the laboratory may warrant further study of function, but it does not allow us to anticipate its magnitude. Conversely, a functional improvement requires analysis to determine its mechanism. This practice maintains accuracy from the cell experiment to the clinical evaluation of an intervention.

What to remember

Respiration, ATP production, membrane potential, and mitophagy are related but different measurements. A laboratory signal alone does not establish better strength, endurance, or longer human life.

Continue with PEPTIDE Academy, Module 9. The complete lessons remain in the Academy; this public article introduces selected concepts.

Product, indication and limits

The elamipretide reading card explains why a product-specific indication cannot be extended to all mitochondrial interventions.

Elamipretide: a specific product and indication

US labeling for FORZINITY identifies elamipretide for improving muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Accelerated approval rests on knee extensor strength as an intermediate clinical endpoint; continued approval may depend on confirmatory benefit.

The FDA snapshot notes that improvements were observed during an open-label extension, rather than superiority on the randomized primary endpoints. This is product-specific evidence and labeling. It does not authorize every preparation called SS-31 or establish antiaging benefit. U.S. labeling checked October 19, 2026: FORZINITY, DailyMed version 10 (published December 12, 2025; prescribing information revised 9/2025). The indicated population and accelerated-approval conditions apply to this product. Other mitochondrial diseases, preparations and longevity claims require their own evidence. In a different population, primary mitochondrial myopathy, the randomized MMPOWER-3 trial did not meet its 24-week primary endpoints (six-minute walk and total fatigue). That result stays separate from the Barth syndrome indication; neither result shows that all mitochondrial research has failed, and neither is an antiaging endorsement. Current label · FDA trial snapshot · MMPOWER-3